After treatment

Management and monitoring are essential elements of the treatment journey

Prior to infusion, ensure patients have baseline tests for liver function,a creatinine, complete blood count (including hemoglobin and platelet count), and troponin-I.1

After infusion, continue to monitor liver function, platelet count,b and troponin-I as described in the Prescribing Information. See the recommended schedule of assessments in the accompanying chart.1

W=week.

aLiver function assessment includes a clinical exam and laboratory testing of hepatic aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), total bilirubin, and prothrombin time. Monitor liver function for 3 months or longer until results are unremarkable (normal clinical exam, total bilirubin, and prothrombin results, and ALT and AST levels below 2 × ULN).

bMonitor platelet counts as well as signs and symptoms of TMA, such as hypertension, increased bruising, seizures, or decreased urine output.

cMonitor platelet counts and troponin-I levels for 3 months or longer until they return to baseline.

=monitoring performed

aLiver function assessment includes a clinical exam and laboratory testing of hepatic aminotransferases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), total bilirubin, and prothrombin time. Monitor liver function for 3 months or longer until results are unremarkable (normal clinical exam, total bilirubin, and prothrombin results, and ALT and AST levels below 2 × ULN).

bMonitor platelet counts as well as signs and symptoms of TMA, such as hypertension, increased bruising, seizures, or decreased urine output.

cMonitor platelet counts and troponin-I levels for 3 months or longer until they return to baseline.

Treat with systemic corticosteroids

To help manage a possible increase in liver aminotransferases, treat all patients with systemic corticosteroids before treatment and continue regimen after treatment1

The recommended treatment regimen is detailed in the Prescribing Information and in the accompanying chart.

The importance of multidisciplinary care

Although ZOLGENSMA is a one-time-only infusion, post-treatment management and continued SMA care are essential for improving outcomes of children with SMA

In addition to regular well visits, it is important that patients with SMA receive respiratory, nutritional, and musculoskeletal support, which are fundamental elements of SMA care that can help maximize functional ability.2,3

Because the loss of motor neurons cannot be reversed, this care should begin as early as possible and continue even after treatment.2,3

Patients treated with ZOLGENSMA may still require the following specialized support2,3:

Physical therapy, occupational therapy, nutritional therapy, and musculoskeletal
specialists and other specialists may be needed to help treat SMA

Patient and caregiver support

A resource for caregivers

Help caregivers understand what to expect after treatment and how to maintain proper SMA care. Fill out the Post-Treatment Plan and share it with your patient’s family prior to the patient being discharged.

Post-Treatment Plan

DOWNLOAD